ArticleOncotarget2017
Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX models.Journal of experimental & clinical cancer research : CR · 2024Article
- Metabolism of primary high-grade serous ovarian carcinoma (HGSOC) cells under limited glutamine or glucose availability.Cancer & metabolism · 2024Article
- Ferroptosis, Metabolic Rewiring, and Endometrial Cancer.International journal of molecular sciences · 2023Review
- Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenografts.Journal of experimental & clinical cancer research : CR · 2023Article
- Tumor metabolism rewiring in epithelial ovarian cancer.Journal of ovarian research · 2023Review
- "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.Frontiers in oncology · 2023Review
- Hallmarks of cancer and hallmarks of aging.Aging · 2022Article
- PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer.Cancer research · 2022Article
- Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer.Cell death & disease · 2022Article
- Fructose-1,6-Bisphosphatase 2 Inhibits Oral Squamous Cell Carcinoma Tumorigenesis and Glucose Metabolism via Downregulation of c-Myc.Oxidative medicine and cellular longevity · 2022Article
- Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.Cell reports. Medicine · 2021Article
- Predictive modeling of gene expression regulation.BMC bioinformatics · 2021Article
- MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC.JCI insight · 2020Article
- Article
- Exploiting Cancer Cells Metabolic Adaptability to Enhance Therapy Response in Cancer.Advances in experimental medicine and biology · 2020Review
- Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy.Clinical and translational medicine · 2019Review
- Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts.Therapeutic advances in medical oncology · 2019Article
- One-Carbon Metabolism: Biological Players in Epithelial Ovarian Cancer.International journal of molecular sciences · 2018Review
- Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells.Scientific reports · 2017Article
- Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells.Cell death & disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deregulated glucose metabolism is observed in cancer but whether this metabolic trait influences response to or is modulated by cytotoxic drugs is unknown. We show here that tumor cells from epithelial ovarian cancer (EOC) patients can be categorized, according to their in vitro viability under glucose starvation, into glucose deprivation-sensitive (glucose-addicted, GA) and glucose deprivation-resistant (glucose non-addicted, GNA). When EOC cells were cultured in the absence of glucose, all samples from platinum (PLT)-sensitive patients felt into the GA group; they disclosed higher expression of glucose metabolism enzymes, higher proliferation rates and in vitro sensitivity to PLT. Moreover, GA patients showed reduced multi-drug resistance pump expression and autophagy, compared to GNA samples. The close association between PLT sensitivity and glucose metabolic profile was confirmed in a xenograft model, where a stringent parallelism between PLT sensitivity/resistance and glucose metabolism was identified. Finally, in a cohort of naïve EOC patients categorized as GA or GNA at diagnosis, Kaplan Meier curves showed that the GA phenotype was associated with significantly better progression-free survival, compared to GNA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.